A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.

Also called NCT05486065

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 245 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05486065
  • EudraCT 2022-000882-41
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Greece, Hungary, Poland, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05486065. Randomized; double masking; primary purpose treatment. Start 2022-08-08 (actual); primary completion 2023-10-12 (actual). Results posted on 2024-11-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05486065
Content hash
a5c48554d976fa0f59396c04fca66ef2dd289da912a7c83c834f13fd83f8d977